Leflunomide for the treatment of rheumatoid arthritis

Bull Rheum Dis. 1999;48(8):1-4.


Leflunomide treatment appears to offer an alternative to methotrexate and sulfasalazine and is a welcome addition to the therapeutic armamentarium for treating active RA. Leflunomide treatment for more than 12 months results in clinically meaningful improvements in disease-specific measures of physical function. The phase 3 trials have shown leflunomide to be as effective as methotrexate and sulfasalazine and an option for initial DMARD therapy. As with all new agents, the long-term safety and value of leflunomide will be determined by use in the clinic.

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Clinical Trials, Phase III as Topic
  • Humans
  • Isoxazoles / therapeutic use*
  • Leflunomide


  • Anti-Inflammatory Agents, Non-Steroidal
  • Isoxazoles
  • Leflunomide